Medicare drug coverage

Descovy: 2027 Medicare Part D coverage

5,495 of 5,495 Part D plans (100%) list Descovy on their 2027 formulary, the plan's list of covered drugs (the same share as 2026). 62% of those require prior authorization, step therapy, or a quantity limit. Plan counts include both Medicare Advantage plans with drug coverage (5,172 MA-PD) and stand-alone drug plans (323 PDP).

License: a US government work, in the public domain (Public Domain Mark 1.0).

Data only, not plan advice. Confirm on Medicare.gov Plan Finder or 1-800-MEDICARE.

2027 compared with 2026

Descovy is number 90 by total Medicare Part D spending in 2024 ($545 million). Plans that list it most often put it on tier 5 (a tier is the cost level a plan puts a drug on; a lower tier usually costs less). Counts use 3 RxNorm products for this name.

Descovy Part D coverage, 2026 and 2027
Measure20262027Change
Part D plans in the file5,5185,495-23
Plans that list it5,517 (100%)5,495 (100%)no change
Prior authorization (of plans that list it)0 (0%)0 (0%)no change
Step therapy (of plans that list it)0 (0%)0 (0%)no change
Quantity limit (of plans that list it)3,612 (65%)3,382 (62%)-3 points
Any of the three (of plans that list it)3,612 (65%)3,382 (62%)-3 points
Not listed or restricted (of all plans)3,613 (65%)3,382 (62%)-3 points

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

For pharmacies and agencies: check a whole drug list against 2027 formularies.

Upload your patient list or your book of clients and Rivvi checks each drug against the CMS 2027 formulary files, plan by plan, so you see tier changes and new limits before the next refill or open enrollment. Free to start. HIPAA BAA included.

Formulary tier

Descovy formulary tier, 2026 and 2027
Tier2026 plans2027 plans
Tier 1163 (3%)123 (2%)
Tier 22 (0%)1 (0%)
Tier 449 (1%)46 (1%)
Tier 55,283 (96%)5,325 (97%)
Tier 620 (0%)0 (0%)

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Plan by plan, 2026 to 2027

4,380 plan IDs are in both files. 50 of them (1%) added prior authorization, step therapy, or a quantity limit for Descovy, and 0 stopped listing it.

Descovy: plans in both 2026 and 2027
Plan by planPlans
Same plan ID in both years4,380
Listed it in 2026, not in 20270 (0%)
Listed it in 2027, not in 20260 (0%)
Moved it to a higher tier43 (1%)
Added prior authorization0 (0%)
Added step therapy0 (0%)
Added a quantity limit50 (1%)
Added at least one of the three50 (1%)
Removed at least one of the three13 (0%)
Plan IDs new in 20271,115
2026 plan IDs not in the 2027 file1,138

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

States from most to least restrictive

Share of 2027 Part D plans offered in each state that leave Descovy off the formulary or list it with prior authorization, step therapy, or a quantity limit. 2 states tie for the highest share, 100%; Hawaii ranks last at 40%. States at the same share are marked Tied and share a rank.

States from most to least restrictive for Descovy, 2027
RankState2027 plansNot listed or restrictedPrior auth or step therapyChange from 2026
Tied 1Montana27100%0%+3 points
Tied 1Wyoming13100%0%+5 points
3Idaho4593%0%+9 points
4Alaska989%0%no change
5Vermont1486%0%+9 points
6New Mexico6881%0%no change
Tied 7New Hampshire2576%0%no change
Tied 7Rhode Island2976%0%+2 points
Tied 7Kentucky12376%0%-2 points
10Maine5275%0%+1 point
Tied 11West Virginia7074%0%-2 points
Tied 11Wisconsin9774%0%+1 point
Tied 11Virginia14574%0%-2 points
Tied 11South Carolina9174%0%+2 points
Tied 11Utah5374%0%no change
16Mississippi10572%0%+1 point
Tied 17New Jersey7470%0%+5 points
Tied 17Georgia15170%0%+1 point
Tied 17Delaware4370%0%-4 points
Tied 20Oklahoma8169%0%-7 points
Tied 20Michigan18369%0%-5 points
Tied 22Iowa6467%0%-1 point
Tied 22Pennsylvania32467%0%+2 points
Tied 22District of Columbia2167%0%-5 points
Tied 22Texas41267%0%-6 points
26Florida54966%0%-5 points
27North Dakota2665%0%-2 points
Tied 28North Carolina17764%0%-13 points
Tied 28Indiana14064%0%-4 points
Tied 30Tennessee15763%0%-8 points
Tied 30Nevada10063%0%-3 points
Tied 30Nebraska5163%0%-6 points
Tied 30Louisiana12663%0%-3 points
Tied 34Arkansas8660%0%-5 points
Tied 34Kansas8460%0%-7 points
36Colorado10658%0%-4 points
Tied 37Washington11456%0%-14 points
Tied 37Arizona14856%0%-8 points
Tied 37Alabama11556%0%-8 points
40California39755%0%+5 points
Tied 41Minnesota6354%0%-5 points
Tied 41Connecticut5454%0%-8 points
43Illinois13353%0%-3 points
44Missouri17152%0%-11 points
45Massachusetts9251%0%-2 points
Tied 46South Dakota3050%0%-3 points
Tied 46Ohio17350%0%no change
Tied 48New York21549%0%-9 points
Tied 48Oregon9249%0%-21 points
50Maryland4943%0%-11 points
51Hawaii5040%0%-6 points

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

By parent organization

164 parent organizations offer 2027 Part D plans. Humana Inc. has the most, 884, and 100% of them leave Descovy off or restrict it.

Descovy coverage by parent organization, 2027
Parent organization2027 plans ↑List itRestrict it (of listing)Not listed or restrictedChange from 2026Plans that added a restriction
BrightSpring Health Services, Inc.2100%0%0%no change0
Community Health Group2100%0%0%no change0
Community Health Plan of Washington2100%0%0%no change0
Denver Health and Hospital Authority2100%0%0%no change0
Elevance Health, Inc. & BCBSMA & BCBSRI & BCBSVT2100%0%0%no change0
Elite Health Systems, Inc.2100%0%0%no change0
Group Health Cooperative of Eau Claire2100%0%0%no change0
Hamaspik of Rockland County, Inc.2100%0%0%-100 points0
ISNP Holdings, LLC2100%100%100%no change0
Kansas Superior Select2100%100%100%no change0
Missouri Healthcare Advisors, LLC2100%100%100%no change0
MultiCare Health Systems2100%100%100%new in 20270
NEIGHBORHOOD HEALTH PLAN OF RHODE ISLAND2100%0%0%no change0
PrimeWest Rural MN Health Care Access Initiative2100%0%0%no change0
Regency ISNP Holdings LLC2100%0%0%no change0
Select Founders, LLC2100%0%0%no change0
Sentara Health Care (SHC)2100%100%100%+100 points2
South Country Health Alliance2100%100%100%no change0
The Regents of the University of California2100%0%0%no change0
Troy Holdings, Inc.2100%0%0%-100 points0
Associated Care Ventures, Inc.3100%100%100%no change0
Aultman Health Foundation3100%100%100%no change0
Banner Health3100%0%0%no change0
Bexar County Hospital District3100%100%100%no change0
Blue Cross Blue Shield of Nebraska3100%100%100%no change0

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Near it by Part D spending

About this data

A plan here is one Part D plan as the CMS formulary files list it: contract, plan, and segment. That covers Medicare Advantage plans with drug coverage and stand-alone drug plans. A plan lists a drug when its formulary has a row for any RxNorm product of that name. When it has several, the row with the lowest tier is the one counted, and restricted means that row has prior authorization, step therapy, or a quantity limit.

A plan with no row for the drug counts as not listing it. That can be a product the file codes another way, so read a low count as a lookup result, not a coverage decision. A state counts every plan the CMS landscape file offers there. Parent organizations are named as CMS names them. The drug list is the top 200 by total Part D spending.

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS Medicare Part D Spending by Drug, 2024 data, as of June 25, 2026. Publisher page

Try it on your own data today.

Free to start. Most teams are using it the same day.